Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
By C. Patrono, C. Baigent, J. Hirsh, G. Roth. Chest, 2008
754 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/24e8193b44d915b14cec4046dfb646db899c94f6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Internal Medicine
Citations in the corpus
- Arterial thrombosis—insidious, unpredictable and deadly (2011, methodology): “are effective strategies to reduce thrombus propagation at sites of vascular injur”
- Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition) (2009, background): “137 Most clinical trials involving the GP IIb/IIIa antagonists have evaluated their use in the treatment of acute coronary syndrome (with or without percutaneous coronary intervention).”
- 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, background): “• Lower daily doses of aspirin, including in patients treated with DAPT, are associated with lower bleeding complications and comparable ischemic protection (56-60) than are higher doses of aspirin.”
- Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, background): “Thienopyridines also interfere with plateletfibrinogen binding and subsequent platelet-platelet interactions.(223) All 3 are prodrugs that must undergo metabolic activation through the hepatic CYP450 system to generate the active metabolites that inhibit the platelet P2Y12 receptor.”
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study (2009, result): “The 3 major findings of the present study are as follows: (1) The onset of the antiplatelet effect of ticagrelor with the PLATO dosing regimen was rapid (a significant antiplatelet effect was observed within 30 minutes of loading) and markedly greater than with highloading-dose clopidogrel; (2) the ”